Baricitinib
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Baricitinib and local guidelines before prescribing.
JAK inhibitor
Mechanism
JAK1 and JAK2 inhibitor.
Uses
Rheumatoid arthritis, atopic dermatitis, alopecia areata, COVID-19 (selected).
Dosing
- Hospitalised patients needing oxygen - dexamethasone 6 mg daily for up to 10 days ; tocilizumab or baricitinib in severe disease (specialist); VTE prophylaxis; prone positioning and respiratory support.
ID: Viral, fungal and parasitic infections
Side effects
Infections, raised lipids, cytopenias, VTE, MACE, herpes zoster.
Interactions
Probenecid raises levels.
Contraindications and cautions
Active infection, pregnancy
Monitoring
FBC, LFT, lipids
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Reduce dose in renal impairment
Overdose and reversal
Supportive
Special advice
MHRA JAK caution groups; reduce dose in renal impairment.
More from the textbook: uses, cautions and other points
- Oral JAK inhibitors - abrocitinib , upadacitinib , baricitinib - effective; MHRA advice: use in people over 65 , smokers, or those with cardiovascular or cancer risk factors only if no suitable alternative (risk of MACE, VTE, cancer, serious infection).
Dermatology: Skin basics, eczema and psoriasis - Abrocitinib / upadacitinib / baricitinib | Oral JAK inhibitors for eczema; caution over 65, smokers, CV or cancer risk.
Dermatology: Skin basics, eczema and psoriasis - JAK (small molecules) | Tofacitinib, baricitinib, upadacitinib, filgotinib | RA, psoriatic arthritis, axial SpA — caution over 65s and smokers (MHRA)
Rheumatology Anatomy Physiology Pharmacology - Biologic and small-molecule targets: anti-TNF (infliximab, adalimumab, etanercept - screen for TB and hepatitis B), anti-IL-6R (tocilizumab - GCA, RA, cytokine release syndrome), anti-IL-17 (secukinumab), anti-IL-12/23 (ustekinumab), anti-IL-5 (mepolizumab - eosinophilic asthma), anti-IL-4R (dupilumab - eczema, asthma), JAK inhibitors …
Cell Biology: Cell cycle, signalling, cell death and stem cells - Oral targeted synthetic DMARDs - tofacitinib, baricitinib, upadacitinib, filgotinib - block Janus kinase signalling (many cytokines at once).
Rheumatology: assessment, investigations and drugs - Vesicular rash in a dermatome on baricitinib | Shingles (JAK inhibitor)
Rheumatology: Emergencies, pregnancy and other systemic diseases - JAK inhibitors (tofacitinib, baricitinib, upadacitinib) | Shingles , serious infections, TB
ID: Hospital infection, the immunocompromised host, vaccination and public health - JAK–STAT pathway - many cytokine receptors signal through Janus kinases - JAK inhibitors (tofacitinib, baricitinib, upadacitinib) block several cytokines at once.
Clinical Immunology: Immune system basics and immunological investigations
Where it is discussed in the book
- Dermatology: Skin basics, eczema and psoriasis (2 mentions)
- Rheumatology Anatomy Physiology Pharmacology (1 mention)
- Rheumatology: assessment, investigations and drugs (1 mention)
- Rheumatology: Emergencies, pregnancy and other systemic diseases (1 mention)
- ID: Viral, fungal and parasitic infections (1 mention)
- ID: Hospital infection, the immunocompromised host, vaccination and public health (1 mention)
- Clinical Immunology: Immune system basics and immunological investigations (1 mention)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (1 mention)
- Cell Biology: Cell cycle, signalling, cell death and stem cells (1 mention)